Global Urinary Incontinence Therapeutics Market 2019-2023 - Product Image

Global Urinary Incontinence Therapeutics Market 2019-2023

  • ID: 4703290
  • Report
  • Region: Global
  • 117 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • Astellas Pharma
  • Merck
  • Novartis
  • Pfizer
  • MORE
The analysts forecast the Global Urinary Incontinence Therapeutics Market to grow at a CAGR of 3.12% during the period 2019-2023.

Covered in this report

The report covers the present scenario and the growth prospects of the urinary incontinence therapeutics market. To calculate the market size, the report considers the revenue generated from the application of urinary incontinence therapeutics across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, urinary incontinence therapeutics market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Astellas Pharma
  • Merck
  • Novartis
  • Pfizer
Market drivers
  • Robust pipeline for the development of drugs for urinary incontinence treatment
  • For a full, detailed list, view the report
Market challenges
  • Patent expiries of drugs
  • For a full, detailed list, view the report
Market trends
  • Shift toward novel formulations
  • For a full, detailed list, view the report
Key questions answered in this report
  • What will the market size be in 2023 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • Astellas Pharma
  • Merck
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Anticholinergic drugs - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • Astellas Pharma
  • Merck
  • Novartis
  • Pfizer
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: MoA of anticholinergic drugs
Exhibit 20: Anticholinergic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Anticholinergic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Others - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Growth in geriatric population in various countries of Americas 2007 and 2017 (%)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Prevalence, rate of urinary incontinence among the US residential care facility residents aged 65 and over 2010 (%)
Exhibit 41: Recent approvals of generic drugs
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: ALLERGAN - Vendor overview
Exhibit 49: ALLERGAN - Business segments
Exhibit 50: ALLERGAN - Organizational developments
Exhibit 51: ALLERGAN - Geographic focus
Exhibit 52: ALLERGAN - Segment focus
Exhibit 53: ALLERGAN - Key offerings
Exhibit 54: ALLERGAN - Key customers
Exhibit 55: Astellas Pharma - Vendor overview
Exhibit 56: Astellas Pharma - Business segments
Exhibit 57: Astellas Pharma - Organizational developments
Exhibit 58: Astellas Pharma - Geographic focus
Exhibit 59: Astellas Pharma - Segment focus
Exhibit 60: Astellas Pharma - Key offerings
Exhibit 61: Astellas Pharma - Key customers
Exhibit 62: Merck - Vendor overview
Exhibit 63: Merck - Business segments
Exhibit 64: Merck - Organizational developments
Exhibit 65: Merck - Geographic focus
Exhibit 66: Merck - Segment focus
Exhibit 67: Merck - Key offering
Exhibit 68: Merck - Key customers
Exhibit 69: Novartis - Vendor overview
Exhibit 70: Novartis - Business segments
Exhibit 71: Novartis - Organizational developments
Exhibit 72: Novartis - Geographic focus
Exhibit 73: Novartis - Segment focus
Exhibit 74: Novartis - Key offerings
Exhibit 75: Novartis - Key customers
Exhibit 76: Pfizer - Vendor overview
Exhibit 77: Pfizer - Business segments
Exhibit 78: Pfizer - Organizational developments
Exhibit 79: Pfizer - Geographic focus
Exhibit 80: Pfizer - Segment focus
Exhibit 81: Pfizer - Key offerings
Exhibit 82: Pfizer - Key customers
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • Astellas Pharma
  • Merck
  • Novartis
  • Pfizer
  • MORE
The author of the report recognizes the following companies as the key players in the global urinary incontinence therapeutics market: Allergan, Astellas Pharma, Merck, Novartis, and Pfizer.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the shift toward novel formulations. Many novel formulations are being developed for the treatment of urinary incontinence and they include the transdermal therapies and mechanism-of-action (MoA)-based therapies such as bete-3- adrenergic agonists and M3 specific anticholinergics.”

According to the report, one driver influencing this market is the robust pipeline for the development of drugs for urinary incontinence treatment. Most of the urinary incontinence therapeutics that are currently in Phase III stage are likely to get approved during the forecast period to augment the growth of the global urinary incontinence market. Furthermore, the increasing number of molecules being developed for urinary incontinence treatment will drive the demand for urinary incontinence therapeutics across the period of forecast.

Further, the report states that one challenge affecting this market is the patent expiries of drugs. Since generic drugs are copies of branded drugs, they can be independently developed only after the expiry of patents of the original products which may impede the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Allergan
  • Astellas Pharma
  • Merck
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4703290
Adroll
adroll